S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gunmen kill 9 Chinese at mine in Central African Republic
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Bank Accounts: Frozen! (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
Nations approve key UN science report on climate change
"Prepare for Five Years of Famine" (Ad)
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gunmen kill 9 Chinese at mine in Central African Republic
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Bank Accounts: Frozen! (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
Nations approve key UN science report on climate change
"Prepare for Five Years of Famine" (Ad)
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gunmen kill 9 Chinese at mine in Central African Republic
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Bank Accounts: Frozen! (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
Nations approve key UN science report on climate change
"Prepare for Five Years of Famine" (Ad)
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gunmen kill 9 Chinese at mine in Central African Republic
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Bank Accounts: Frozen! (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
Nations approve key UN science report on climate change
"Prepare for Five Years of Famine" (Ad)
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
NYSE:AIM

AIM ImmunoTech - AIM Stock Forecast, Price & News

$0.48
+0.01 (+2.01%)
(As of 03/17/2023 08:53 PM ET)
Add
Compare
Today's Range
$0.47
▼
$0.49
50-Day Range
$0.45
▼
$0.77
52-Week Range
$0.29
▼
$1.38
Volume
117,000 shs
Average Volume
269,596 shs
Market Capitalization
$23.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AIM stock logo

About AIM ImmunoTech (NYSE:AIM) Stock

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Receive AIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter.

AIM Stock News Headlines

March 17, 2023 | baystreet.ca
Biotech Sector Delivering Increased Optimism in Battle Against Pancreatic Cancer
March 16, 2023 | tmcnet.com
AIM ImmunoTech Announces Late-Breaking Presentation at the
March 20, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
March 16, 2023 | finance.yahoo.com
AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
March 8, 2023 | tmcnet.com
AIM ImmunoTech Announces Publication of New Analysis of
March 6, 2023 | finanznachrichten.de
AIM ImmunoTech Inc.: AIM ImmunoTech Issues Letter to Stockholders
February 28, 2023 | finance.yahoo.com
AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
February 17, 2023 | tmcnet.com
AIM ImmunoTech to Participate in Solve M.E.
March 20, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
February 17, 2023 | finance.yahoo.com
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
February 17, 2023 | marketwatch.com
Warts Therapeutics Market Size 2023 : Emerging Technologies, Opportunity and Forecast to 2028
January 17, 2023 | msn.com
AIM ImmunoTech gains on research deal for lead asset
January 17, 2023 | finanznachrichten.de
AIM ImmunoTech Inc.: AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
January 17, 2023 | proactiveinvestors.com
AIM ImmunoTech shares rise on news of pancreatic cancer research partnership with AstraZeneca and Erasmus Medical Center
January 9, 2023 | tmcnet.com
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands
January 9, 2023 | proactiveinvestors.com
AIM ImmunoTech broadens patent portfolio with new Netherlands utility patent
January 5, 2023 | benzinga.com
AIM ImmunoTech, InnSuites Hospitality Trust And 2 Other Penny Stocks Insiders Are Aggressively Buying
January 5, 2023 | tmcnet.com
AIM ImmunoTech to Present at the 'Virtual Investor 2023 Companies to Watch Event'
January 5, 2023 | finance.yahoo.com
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
December 28, 2022 | msn.com
AIM ImmunoTech's Return On Capital Employed Insights
December 19, 2022 | msn.com
Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket
December 12, 2022 | proactiveinvestors.com
AIM ImmunoTech promotes Christopher McAleer to the role of scientific officer
December 8, 2022 | proactiveinvestors.com
AIM ImmunoTech reports positive safety, tolerability, and biological activity data from Phase 1 Ampligen study
December 8, 2022 | finance.yahoo.com
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
November 15, 2022 | proactiveinvestors.com
AIM ImmunoTech says cash position expected to fund operations through end of 2023
November 15, 2022 | finanznachrichten.de
AIM ImmunoTech Inc.: AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 | proactiveinvestors.com
AIM ImmunoTech shows positive results using Ampligen in treating triple negative breast cancer
See More Headlines
Receive AIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter.

AIM Company Calendar

Last Earnings
11/16/2021
Today
3/20/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:AIM
CUSIP
N/A
CIK
946644
Web
aimimmuno.com
Phone
(352) 448-7797
Fax
215-988-1739
Employees
21
Year Founded
1990

Profitability

EPS (Most Recent Fiscal Year)
($0.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-19,130,000.00
Net Margins
-15,598.51%
Pretax Margin
-15,598.51%
Return on Equity
-42.06%
Return on Assets
-40.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.21
Quick Ratio
14.21

Sales & Book Value

Annual Sales
$135,000.00
Price / Sales
171.55
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.21 per share
Price / Book
0.40

Miscellaneous

Outstanding Shares
48,049,000
Free Float
48,039,000
Market Cap
$23.16 million
Optionable
Not Optionable
Beta
-0.24

Social Links


Key Executives

  • Thomas Kenwood Equels
    Executive Vice Chairman, President & CEO
  • Peter W. Rodino
    COO, Secretary & General Counsel
  • Robert Dickey
    Chief Financial Officer
  • David R. Strayer
    Chief Medical Officer
  • Christopher McAleer
    Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AIM Stock - Frequently Asked Questions

How have AIM shares performed in 2023?

AIM ImmunoTech's stock was trading at $0.3119 on January 1st, 2023. Since then, AIM shares have increased by 54.5% and is now trading at $0.4820.
View the best growth stocks for 2023 here.

How were AIM ImmunoTech's earnings last quarter?

AIM ImmunoTech Inc. (NYSE:AIM) announced its earnings results on Tuesday, November, 16th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.01. The business earned $0.03 million during the quarter. AIM ImmunoTech had a negative net margin of 15,598.51% and a negative trailing twelve-month return on equity of 42.06%.

What other stocks do shareholders of AIM ImmunoTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX).

What is AIM ImmunoTech's stock symbol?

AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM."

Who are AIM ImmunoTech's major shareholders?

AIM ImmunoTech's stock is owned by a number of retail and institutional investors. Top institutional investors include Morgan Stanley (1.91%). Insiders that own company stock include Stewart Appelrouth, Thomas K Equels and Thomas K Equels.
View institutional ownership trends.

How do I buy shares of AIM ImmunoTech?

Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AIM ImmunoTech's stock price today?

One share of AIM stock can currently be purchased for approximately $0.48.

How much money does AIM ImmunoTech make?

AIM ImmunoTech (NYSE:AIM) has a market capitalization of $23.16 million and generates $135,000.00 in revenue each year. The company earns $-19,130,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How can I contact AIM ImmunoTech?

AIM ImmunoTech's mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The official website for the company is aimimmuno.com. The company can be reached via phone at (352) 448-7797, via email at ir@aimimmuno.com, or via fax at 215-988-1739.

This page (NYSE:AIM) was last updated on 3/20/2023 by MarketBeat.com Staff